Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 10:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 3,875 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: fast Clear all

Conditions: Acute Decompensated Heart Failure
Interventions: Reprieve Decongestion Management System, Diuretic; Device · Drug
Lead sponsor: Reprieve Cardiovascular, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 16
States / cities: Fairhope, Alabama • Irvine, California • Washington D.C., District of Columbia + 12 more

Conditions: Acute Kidney Injury, Acute Renal Failure, Heart Failure
Interventions: Dilute unfractionated heparin, Standard concentration unfractionated heparin; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Group B Streptococcus Neonatal Sepsis
Interventions: Not listed
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Disorder of Glucose Regulation
Interventions: Sitagliptin-Metformin, Metformin, Placebo pill; Drug
Lead sponsor: Woman's; Other
Eligibility: 18 Years to 42 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Acute Kidney Injury
Interventions: Not listed
Lead sponsor: Abbott RDx Cardiometabolic; Other
Eligibility: 21 Years and older
Enrollment: 1,001 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 25
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 21 more

Conditions: Chronic Kidney Injury
Interventions: CXA-10, CXA-10 placebo; Drug
Lead sponsor: Complexa, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Chronic Pain, Depression, PTSD Symptoms, Sleep
Interventions: Traditional Chinese Acupuncture, Tennant™ Biomodulator Treatment, Transcutaneous electrical nerve stimulation (TENS) Treatment; Other · Device
Lead sponsor: Samueli Institute for Information Biology; Other
Eligibility: 18 Years to 60 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Fort Sam Houston, Texas

Conditions: Advanced Malignancies
Interventions: parsaclisib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 82 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Tustin, California • Hialeah, Florida • Orlando, Florida + 1 more

Conditions: Migraine, Cluster Headache, Trigeminal Autonomic Cephalgia, Hemicrania Continua, Paroxysmal Hemicrania, SUNCT, Short-Lasting Unilateral Neuralgiform Headache With Conjunctival Injection and Tearing
Interventions: Oral capsaicin, Topical capsaicin, Intranasal capsaicin, Cold Water Irrigation, Medical Air, Low Flow Oxygen, High Flow Oxygen; Drug · Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 371 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy Volunteers
Interventions: E2086, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Glendale, California

Conditions: Melanoma
Interventions: Spartalizumab, Placebo, Dabrafenib, Trametinib; Biological · Other · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 568 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 12
States / cities: Encinitas, California • Orange, California • San Francisco, California + 9 more

Conditions: Covid19
Interventions: COVID-19 SARS-CoV IgG/IgM antibody rapid test; Device
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 21 Years and older
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Wauwatosa, Wisconsin

Conditions: Septic Shock
Interventions: Levo-Carnitine, placebo; Drug
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 14
States / cities: Birmingham, Alabama • Sacramento, California • Wilmington, Delaware + 9 more

Conditions: Healthy Volunteers
Interventions: Mobocertinib; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy
Interventions: Pregabalin controlled release, 330 mg, 600- 750 calorie, Pregabalin controlled release, 330 mg, fasted, Pregabalin immediate release, 300 mg; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Overweight and Obesity, Eating Behavior
Interventions: Placebo, Bromocriptine-QR; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 35 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Obesity, Healthy Volunteers
Interventions: S309309, Itraconazole; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Pregnancy Related, Hormone Deficiency
Interventions: Proov Test; Diagnostic Test
Lead sponsor: MFB Fertility; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Healthy Participants
Interventions: TAK-418, TAK-418 Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Glendale, California

Conditions: Opioid Dependence
Interventions: INDV-2000, Placebo; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Fibromyalgia
Interventions: Prolonged Nightly Fasting, Health Education Control; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Seizures Associated With EMAS
Interventions: GWP42003-P, Placebo; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 1 Year to 18 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 10
States / cities: Birmingham, Alabama • Sacramento, California • Atlanta, Georgia + 7 more

Conditions: Depressive Disorder, Major
Interventions: Esketamine, Placebo, Standard of Care; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 18
States / cities: San Diego, California • Farmington, Connecticut • Miami, Florida + 14 more

Conditions: Healthy
Interventions: Pantoprazole Sodium 40 mg delayed-release tablets, PROTONIX® 40 mg delayed-release tablets.; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 2
States / cities: Saint Charles, Missouri • Houston, Texas

Search by objective public record fields.

Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve Decongestion Management System (DMS)

A Comparison of Dilute Versus Concentrated Heparin for CRRT Anticoagulation

Rapid Detection of Group B Strep- 35-37 Week Study

Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent GDM

Rapid Evaluation of Acute Kidney Injury With NGAL in Acutely Ill Patients in the ICU

Oral CXA-10 Study in Healthy Volunteers

Comparing Acupuncture, BioModulator, and Transcutaneous Electrical Nerve Stimulation for Symptomatic Treatment of Chronic Pain.

To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.

Pain Biomarker Study

A Study of E2086 in Healthy Adult Participants

A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

Point of Care Evaluation of Novir 2019-nCoV Immunoglobulin G/ Immunoglobulin M (IgG/IgM) Antibody Test (Collodial Gold)

Rapid Administration of Carnitine in sEpsis

A Study to Assess Absolute Bioavailability (ABA) of Mobocertinib (TAK-788) and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of Carbon-14 ([14C])-Mobocertinib in Male Healthy Participants

Investigation Of Absorption And Pharmacokinetics Of A Single Dose Of Controlled Release Pregabalin Tablet Administered Fasted In The Evening or Immediately Following A 600-750 Calorie Evening Meal As Compared To Single Dose Of Immediate Release Pregabalin Capsule In Healthy Volunteers

Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM

Effect of Administration of Itraconazole on the Pharmacokinetics of S-309309 in Healthy Participants

Relationship Between Fertility Hormone Patterns and Pregnancy Rates.

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Oral Single Dose of TAK-418 in Healthy Participants

INDV-2000 First in Human

Prolonged Nightly Fasting in Fibromyalgia

Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures

54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide

Pantoprazole Sodium 40 mg DR Tablets Under Fasting Conditions